238 related articles for article (PubMed ID: 17408938)
41. A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red.
Halstead BW; Zwickl CM; Morgan RE; Monteith DK; Thomas CE; Bowers RK; Berridge BR
J Appl Toxicol; 2006; 26(2):169-77. PubMed ID: 16278808
[TBL] [Abstract][Full Text] [Related]
42. Experimental phospholipidosis induced by 4,4'-diethyl-aminoethoxyhexestrol. Morphological and biochemical interpretations.
Tashiro Y; Watanabe Y; Enomoto Y
Acta Pathol Jpn; 1983 Sep; 33(5):929-42. PubMed ID: 6316720
[TBL] [Abstract][Full Text] [Related]
43. Amiodarone-induced phospholipidosis in rat alveolar macrophages.
Reasor MJ; Ogle CL; Walker ER; Kacew S
Am Rev Respir Dis; 1988 Mar; 137(3):510-8. PubMed ID: 2830811
[TBL] [Abstract][Full Text] [Related]
44. In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats.
Kodavanti UP; Lockard VG; Mehendale HM
J Biochem Toxicol; 1990; 5(4):245-51. PubMed ID: 1965728
[TBL] [Abstract][Full Text] [Related]
45. Types of interaction of amphiphilic drugs with phospholipid vesicles.
Joshi UM; Kodavanti PR; Coudert B; Dwyer TM; Mehendale HM
J Pharmacol Exp Ther; 1988 Jul; 246(1):150-7. PubMed ID: 3392651
[TBL] [Abstract][Full Text] [Related]
46. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals.
Jiang Z; Reilly J
J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505
[TBL] [Abstract][Full Text] [Related]
47. The Application of Paraphenylenediamine Staining for Assessment of Phospholipidosis.
Shirai N; Geoly FJ; Bobrowski WF; Okerberg C
Toxicol Pathol; 2016 Dec; 44(8):1160-1165. PubMed ID: 27770109
[TBL] [Abstract][Full Text] [Related]
48. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells.
Noor F; Niklas J; Müller-Vieira U; Heinzle E
Toxicol Appl Pharmacol; 2009 Jun; 237(2):221-31. PubMed ID: 19332084
[TBL] [Abstract][Full Text] [Related]
49. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
50. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential.
Tomizawa K; Sugano K; Yamada H; Horii I
J Toxicol Sci; 2006 Oct; 31(4):315-24. PubMed ID: 17077586
[TBL] [Abstract][Full Text] [Related]
51. Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
Alakoskela JM; Vitovic P; Kinnunen PK
ChemMedChem; 2009 Aug; 4(8):1224-51. PubMed ID: 19551800
[TBL] [Abstract][Full Text] [Related]
52. Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration.
Yudate HT; Kai T; Aoki M; Minowa Y; Yamada T; Kimura T; Ono A; Yamada H; Ohno Y; Urushidani T
Toxicology; 2012 May; 295(1-3):1-7. PubMed ID: 22426296
[TBL] [Abstract][Full Text] [Related]
53. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence.
Vonderfecht SL; Stone ML; Eversole RR; Yancey MF; Schuette MR; Duncan BA; Ware JA
Toxicol Pathol; 2004; 32(3):318-25. PubMed ID: 15204973
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells.
Diaz D; Scott A; Carmichael P; Shi W; Costales C
Mutat Res; 2007 Jun; 630(1-2):1-13. PubMed ID: 17446119
[TBL] [Abstract][Full Text] [Related]
55. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity.
Jørgensen S; Nielsen EØ; Peters D; Dyhring T
J Neurosci Methods; 2008 Mar; 169(1):168-76. PubMed ID: 18222006
[TBL] [Abstract][Full Text] [Related]
56. Drug-induced phospholipidosis.
Lüllmann H; Lüllmann-Rauch R; Wassermann O
Ger Med; 1973; 3(3-4):128-35. PubMed ID: 4370610
[No Abstract] [Full Text] [Related]
57. Pulmonary changes induced by amphophilic drugs.
Hruban Z
Environ Health Perspect; 1976 Aug; 16():111-8. PubMed ID: 189997
[TBL] [Abstract][Full Text] [Related]
58. Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.
Bocchini N; Giantin M; Crivellente F; Ferraresso S; Faustinelli I; Dacasto M; Cristofori P
J Appl Toxicol; 2015 Jan; 35(1):90-103. PubMed ID: 25580480
[TBL] [Abstract][Full Text] [Related]
59. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
Ikeda K; Hirayama M; Hirota Y; Asa E; Seki J; Tanaka Y
Biochem Biophys Res Commun; 2008 Dec; 377(1):268-74. PubMed ID: 18840403
[TBL] [Abstract][Full Text] [Related]
60. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.
Shahane SA; Huang R; Gerhold D; Baxa U; Austin CP; Xia M
J Biomol Screen; 2014 Jan; 19(1):66-76. PubMed ID: 24003057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
